

### Announcement No. 12/2007 16 august 2007

# **Coloplast continues share buy-back**

# As mentioned in the company's interim financial statements for nine months 2006/07, the Board of Directors of Coloplast has decided to initiate the remaining part of the share buy-back programme of DKK 1 billion within current fiscal year.

The programme is expected to be exercised in the period from 16 August to 30 September 2007, and the volume of trading in own shares will be limited to a maximum total market value of DKK 500 million.

The buy-back programme is being launched within the scope of the existing authority granted by the shareholders at the Annual General Meeting in December 2006 for the repurchase of up to 10% of the company's share capital. It will be proposed to the Annual General Meeting that the shares repurchased under the programme be cancelled.

The buy-back programme will be structured in compliance with the rules of Commission Regulation No. 2273/2003 of 22 December 2003, which ensures that the company is protected against violation of insider legislation in connection with the buy-back.

The company has entered into a contract with Nordea Bank Danmark A/S, in which Nordea agrees to act as lead manager of the buy-back programme. According to a separate contract concluded with the company, Nordea will purchase shares on behalf of Coloplast A/S. Nordea has also agreed under the contract to make its trading decisions in relation to the shares in the company independently of, and without influence by, the company.

Coloplast is entitled to stop the repurchase during the life of the buy-back programme in the event that significant changes are recorded in the company's affairs or in the market. If the company decides to stop the repurchase, such a decision will be disclosed to the public by announcement to the Copenhagen Stock Exchange. Nordea will subsequently no longer be entitled to purchase shares in Coloplast A/S on behalf of the company.

The buy-back programme is subject to the following terms:

- The volume of trading in own shares will be limited to a maximum total market value of DKK 500 million.
- The maximum number of shares to be acquired under the buy-back programme is 1,200,000 shares of DKK 5 each at a total nominal value of DKK 6,000,000, equivalent to 2.5% of the share capital of Coloplast A/S.
- The maximum number of shares to be purchased in the company per daily market session is 25% of the average volume of shares in the company traded on the Copenhagen Stock Exchange during the latest 20 days before the trading day on Copenhagen Stock Exchange.
- During the life of the buy-back programme no shares will be purchased at a price exceeding the higher of the following two prices:
  i) the price of the last independent trade and
  ii) the highest current independent bid on the Copenhagen Stock Exchange.
- Details of all transactions executed under the buy-back programme will be publicly disclosed no later than the end of the seventh daily market session.



Ostomy care Urology & Continence care Wound & Skin care Breast care

Coloplast's holding of own shares is 3,003,826 shares equal to 6.3% of the company's total share capital before initiation of the share buy-back programme.

Sten Scheibye President, CEO

## **Further information**

Investors and financial analysts Lene Skole Executive Vice President, CFO Tel. + 45 4911 1665 E-mail: dklsk@coloplast.com

Jørgen Fischer Ravn Head of Investor Relations Tel. 3085 1308 E-mail <u>dkjfr@coloplast.com</u>

### Press and the media

Jens Tovborg Jensen Head of Media Relations Tel. + 45 3085 1922 E-mail: dkjto@coloplast.com

This announcement is available in a Danish and an English version. In case of discrepancies, the Danish version will prevail.